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Abstract
Gene suppression approaches have emerged over the last 20 years as a novel therapeutic approach for the treatment
of neurodegenerative diseases. These include RNA interference and anti-sense oligonucleotides, both of which act at
the post-transcriptional level, and genome-editing techniques, which aim to repair the responsible mutant gene. All
serve to inhibit the expression of disease-causing proteins, leading to the potential prevention or even reversal of
the disease phenotype. In this review we summarise the main developments in gene suppression strategies, using
examples from Huntington’s disease and other inherited causes of neurodegeneration, and explore how these might
illuminate a path to tackle other proteinopathy-associated dementias in the future.
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Background
Gene suppression approaches refer to targeted molecular
genetic therapies that serve to lower the expression of spe-
cific genes. The term “gene silencing” has also been used
to describe these methods; however, this term should be
considered a misnomer as complete gene inactivation does
not occur, and might not be desirable. Such techniques
have made enormous progress over the last 20 years, and
show great promise for the treatment of inherited neurode-
generative diseases arising from a known genetic mutation.
Neurodegenerative diseases that result from the toxic
gain-of-function of a mutant protein or non-coding
RNA that are without a significant loss-of-function are
ideal candidates for gene suppression approaches. There
are many strategies to lower the amount of toxic disease
proteins that result from single gene mutations, includ-
ing both post-transcriptional inhibition such as RNA
interference (RNAi), anti-sense oligonucleotides (ASOs)
and catalytic nucleic acids, and genome editing tech-
niques such as zinc finger proteins (ZFPs) and CRISPR/
Cas9. The great benefit of interventions at the gene sup-
pression level, as opposed to interventions aimed at the
toxic protein itself, is that the plethora of potentially
negative downstream cellular pathogenic effects that
may arise from the abnormal functioning of a single pro-
tein are all reduced as a consequence of treatment.
In this review we will use examples from Huntington’s
disease (HD), in respect of which a worldwide collaborative
research effort has led to the swift progression of gene
suppression approaches, from in-vitro and in-vivo develop-
ment through to a clinical trial of a Huntingtin-lowering
therapy that is currently in progress [1]. Huntington’s
disease is an autosomal dominant, neurodegenerative
condition caused by a CAG expansion in exon 1 of the
gene encoding the Huntingtin (HTT) protein. The pres-
ence of the mutant gene leads to the adult onset of chorea,
psychiatric symptoms and cognitive decline, and is fatal
after 15–20 years [2]. In addition, examples of gene sup-
pression approaches in amyotrophic lateral sclerosis (ALS)
[3] will be discussed. However, lessons learnt from
development of gene suppression technologies in these
conditions could equally be applied to any dementia or
neurodegenerative condition in which the responsible
disease protein is known. Indeed the potential of lowering
tau protein for the treatment of Alzheimer’s disease (AD)
and other tauopathies has been demonstrated recently [4],
as well as targeting alpha-synuclein (SNCA) [5] and
leucine-rich-repeat kinase 2 (LRRK2) [6] for Parkinson’s
disease (PD), and ataxin-2 for the treatment of spino-
cerebellar ataxia type 2 (SCA2) [7], sporadic ALS and
frontotemporal dementia (FTD) [8].
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Post-transcriptional gene suppression
Post-transcriptional gene suppression refers to approaches
that trigger the cleavage, enhanced degradation or transla-
tional suppression of the target mRNA. They include
RNAi, ASOs and catalytic nucleic acids (ribozymes and
DNA enzymes). Ultimately all of these mechanisms serve
to modulate translation efficiency, thus lowering the
amount of protein expressed [9] (see Fig. 1).
RNA interference
Endogenous RNAi is an evolutionarily conserved process
within cells, whereby native, non-coding, double-stranded
RNA sequences elicit post-transcriptional gene suppres-
sion, typically by causing the destruction of specific mRNA
molecules, thereby regulating mRNA expression [10] (see
Fig. 2). Two types of small RNA molecules—endogenous
genomically non-coding RNAs called microRNA (miRNA)
and exogenous short-interfering RNA (siRNA)—can
bind to other specific mRNA molecules and increase or
decrease their activity.
This well-described mechanism is comprised of a
number of steps [11]:
1. Within the nucleus, miRNAs are transcribed by
RNA polymerase II (pol II) and pol III promoters to
form stem–loop structures known as primary
miRNAs (pri-miRNAs).
2. pri-miRNAs are cleaved by the endoribonuclease
enzyme Drosha to form a precursor miRNA
(pre-miRNA) hairpin-like structure.
3. pre-miRNAs are exported to the cytoplasm by
Exportin-5.
4. In the cytoplasm, the pre-miRNA is further
processed by another endoribonuclease enzyme
Dicer to create a mature miRNA complex.
5. The antisense or “guide strand” of the (endogenous
miRNA or exogenous siRNA) complex is loaded into
the RNA-induced silencing complex (RISC), which
is located in the cytoplasm, and the sense or
“passenger” strand is degraded.
6. The guide strand targets the RISC to its
complementary mRNA. Perfect base pair
matching in the case of siRNA leads to
Argonaut-2 (Ago-2)-mediated cleavage of the
target and complete translational inhibition.
Imperfect complementarity in the case of miRNA
leads to translational repression.
siRNAs differ from miRNAs in that miRNAs typically
have incomplete base pairing to a target and inhibit the
translation of many different mRNAs with similar
sequences. siRNAs, in contrast, typically base-pair
perfectly and induce mRNA cleavage only in a single,
specific target.
Fig. 1 Mechanisms of post-transcriptional gene suppression. a Ribozymes act in the cytoplasm where they hybridise complementary
mature mRNA sequences and induce catalytic cleavage. b ASOs bind to complementary mRNA targets, leading to RNAse H1-induced
mRNA cleavage. They are able to target both pre-mRNA in the nucleus and mature mRNA in the cytoplasm. c RNAi occurs in the
cytoplasm and leads to the degradation of mature mRNA via a complex and highly regulated process. ASO: anti-sense oligonucleotide,
AS-siRNA: antisense short interfering RNA, RISC: RNA-induced silencing complex, RNAi: RNA interference (Reproduced from Godinho et al. [9]
with permission from Elsevier)
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Intensive research has been carried out to generate ef-
fectors that manipulate the RNAi pathway to suppress
the expression of a particular gene of interest. These
have taken the form of siRNAs that include short hair-
pin RNAs (shRNAs), and artificial miRNAs, all of which
aim to degrade mature, spliced mRNA in the cytosol.
siRNAs are comprised of 20–25 base pairs, are proc-
essed by Dicer and ultimately lead to Ago-2-mediated
cleavage of the target mRNA, to interfere with the
expression of specific genes with complementary
nucleotide sequences. They can be delivered into cells in
liposome formulations [12], nanoparticles [13] or as
chemically modified single-stranded siRNAs [14, 15].
siRNAs do not cross an intact blood–brain barrier
(BBB), are not soluble in artificial CSF and when injected
directly into the brain do not typically penetrate the
plasma membrane without modification.
Researchers have therefore used RNA expressed from
viral gene therapy vectors to achieve stable expression in
brain regions of interest. The RNA from the viral gen-
ome is processed by Dicer to RNAi (e.g. shRNAs and
artificial miRNAs). shRNAs delivered into cells using
viral vectors have been shown to cause extremely high
levels of translational suppression [16, 17], although this
has also caused saturation of the endogenous RNAi
machinery [18]. More recently, siRNAs have been em-
bedded into artificial miRNA backbones to achieve
mRNA suppression without the build-up of antisense
precursors in the cell [11].
RNAi as therapeutics in neurodegenerative disease
RNAi has been investigated widely in HD, and many po-
tential scientific hurdles have been overcome. It is worth
bearing in mind that the underlying principles of RNAi
for the potential treatment of HD could also be applied
to other causes of dementia. Initially, RNAi to lower the
amount of Huntingtin protein (HTT) was shown in vitro
to improve cell survival in cellular models of HD [19]. In
2005 the first in-vivo studies of RNAi were carried out.
Single bilateral injections of AAV-encased anti-HTT
shRNA were delivered into the striatum of HD trans-
genic mice (N171-82Q), leading to significant reductions
in both mutant HTT mRNA levels and in the formation
of HTT inclusions (which are a pathognomic feature of
HD) [20]. Improvements in certain motor symptoms
were also found. Similar results have also been reported
in other mouse models of HD (R6/1), with increased
presence of striatal markers (DARPP-32) and preproen-
kephalin (ppENK) following treatment [16].
Non-viral delivery systems have also been tested, using
nanoparticles to deliver lipid formulated siRNAs via the
intracerebral ventricular route in the R6/2 mouse model
of HD. This lowered mutant HTT mRNA levels and
inclusions, and reduced brain atrophy. Sustained effects
Fig. 2 miRNA processing pathway. miRNA: microRNA, pre-miRNA: precursor miRNA, pri-miRNA: primary miRNA, RISC: RNA-induced silencing
complex (Reproduced from O’Kelly et al. [101] with permission from Nature Publishing Group)
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including delayed onset of motor symptoms and improved
survival were seen [21]. Delivery of cholesterol-conjugated
siRNA duplexes targeting human HTT mRNA into the
striatum have also shown feasibility and efficacy in an
AAV mouse model of HD [22].
These studies all administered treatment in pre-
symptomatic HD mice, but treatment in symptomatic
HD mice has also successfully reduced HTT protein
levels, reduced inclusions and improved histopathology
[23]. The impact on HD behavioural deficits and any
potential reversal of phenotype remain to be seen. In the
case of prion disease, hippocampal delivery of lentivirus
expressing shRNA targeting prion protein (PrP) signifi-
cantly prolonged survival of mice with established prion
disease. The onset of behavioural deficits was prevented
and spongiform degeneration decreased when the same
treatment was administered to mice with early prion dis-
ease [24]. This highlights the importance of the timing
of gene suppression therapies in the treatment of neuro-
degenerative disorders.
The earlier siRNA studies in HD animal models did
not affect the endogenous levels of wild-type HTT pro-
tein—only the disease-causing transgene was reduced. In
addition, the models were also all expressing a small N-
terminal fragment of the mutant protein (thought to be
the potential disease-causing species in HD [25]) and
not full-length mutant HTT. Attempting to target the
full-length mutant HTT mRNA, whilst leaving the
mRNA of the wild-type allele unaffected, has proven to
be very difficult in cells derived from HD patients
(although newer strategies are being developed to try
and do just that—see later). An alternative approach is to
non-specifically lower both mutant and wild-type HTT to
a degree which improves pathology whilst maintaining
safety and tolerability in the face of wild-type HTT loss. A
40–60% reduction in both endogenous and mutant HTT
extends the lifespan and prevents motor deficits, without
causing toxicity in both fragment [26] and full-length [17]
mouse models of HD. Again, this was also found to be the
case when treating symptomatic HD rodents [27, 28].
RNAi testing in HD non-human primates (adult
rhesus monkeys) has also demonstrated the safety of
partially reducing endogenous wild-type HTT following
delivery of AAV vectors expressing artificial miRNAs
and shRNAs. A 45% reduction in wild-type HTT did not
induce any pathology or symptomatology [29] and sus-
tained knock-down was still evidenced and well tolerated
after 6 months [30]. These findings have since been rep-
licated in further studies showing that direct infusion of
siRNA into the rhesus putamen lowered HTT to a simi-
lar degree and that there was a partially sustained effect
up to 39 days post treatment [31, 32]. Therefore partial
lowering of both mutant and wild-type HTT may be a
viable treatment strategy in HD.
Translation of this finding to other genetic forms of neu-
rodegenerative disease is not assured. The consequences of
lowering levels of endogenous wild-type protein needs to
be investigated carefully when non-allele-specific targeting
is considered for conditions in which only the mutant pro-
tein is pathogenic. However, for neurogenetic disorders in
which misfolding of the mutant protein corrupts
native/wild-type protein, recruiting them to spread
pathology, non-allele-specific targeting may be required
for pharmacologic effect.
Anti-sense oligonucleotides
ASOs are single-stranded DNA molecules consisting
of 16–22 bases, which are complementary to the tar-
get pre-mRNA. ASOs have a more upstream site of
action than RNAi effectors that act on mature, spliced
mRNA species. Upon binding, ASOs recruit RNaseH1 (an
endogenous enzyme that recognises RNA/DNA duplexes),
which degrades the target pre-mRNA. Alternatively, ASOs
may obstruct the interactors of the pre-mRNA leading to
translational inhibition or modulation of splicing [11].
Over the last 20 years, modifications of ASOs have
improved their suitability for therapeutic application in
neurodegenerative diseases. These modifications include
the following:
1. Sulphur substitution for oxygen in the phosphate of
the phosphate inter-nucleotide linkages or backbone
of the ASO molecule, thus increasing resistance to
nucleases and improving protein binding.
2. Multiple potential alterations to the sugar moiety of
the nucleotide which increase binding affinity to the
target mRNA, increase resistance to nucleases and
decrease toxicity to varying degrees. Importantly,
most sugar modifications lead to failure to recruit
the RNaseH1 enzyme. Therefore, when RNaseH1
activity is desired, nucleotides at the ends of the
ASO can be modified to improve binding affinity
and resistance to nucleases, while leaving a stretch
of unmodified nucleotides in the middle that can
engage RNaseH1.
Engineering ASOs with specific desired characteristics
can be achieved by incorporating one or more of these
chemical modifications into their design. A diverse range
of ASOs is therefore possible, with different potencies,
pharmacokinetics and pharmacodynamics, as well as dif-
ferent targets.
ASOs as therapeutics in neurodegenerative disease
ASOs are currently being tested in early-stage clinical
trials in patients with HD and ALS [3], and have been
approved by the US Food and Drug Administration
(FDA) for the treatment of patients with spinal muscular
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atrophy (SMA) [33, 34] (see section “Recent and ongoing
clinical trials of gene suppression”). In the case of HD,
since September 2015 an ASO with a modified sugar
group (MOE) targeting human HTT mRNA has been de-
livered by lumbar intrathecal bolus injection to patients
with early-stage HD as part of a phase 1/2a clinical trial
sponsored by Ionis Pharmaceuticals [1].
This ASO has been tested in pre-clinical studies and is
predicted to lower total HTT levels in a dose-dependent
manner. It has been shown to reverse behavioural phe-
notypes in BACHD and YAC128 mouse models of HD
[35] and to ameliorate key striatal gene expression
changes (YAC128) [36]. As was the case with RNAi,
non-allele-specific suppression with subsequent lowering
of endogenous HTT did not cause any toxicity. Pheno-
typic improvements were greatest when treatment was
initiated earlier in the disease course, and were sustained
for many months following termination of treatment
[37]. Suppression of the target mRNA itself also lasted
for 12 weeks after a single administration of ASO in
these mice [35]. This has enormous implications for the
timing of intervention and the dosing frequency that
would be required for HD patients; this is of particular
importance given the relatively invasive route required
for drug administration (see later).
Catalytic nucleic acids
Ribozymes
Ribozymes are naturally occurring RNA molecules com-
prising two flanking sequences that enable specific bind-
ing to target mRNA, and an effector catalytic core that
cleaves the mRNA substrate. The mRNA fragments are
then degraded by the cell [9].
Hammerhead ribozymes (a specific class of ribozymes
30–40 nucleotides in length), delivered using an AAV
vector, have been shown to result in 60% reduction of
mHTT mRNA when delivered to HEK293 cells express-
ing mHTT exon 1 [38]. Direct striatal injection of these
ribozymes into a transgenic HD mouse (R6/1) also led
to a 30% reduction of mHTT RNA in the mouse brain
[38], but the impact on motor and behavioural symp-
toms has not been studied. AAV delivery of a ribozyme
against alpha-synuclein into the substantia nigra of a rat
model of PD reduced alpha-synuclein protein levels and
neuronal loss [39]. Finally, a new generation of ribo-
zymes (hepatitis delta virus (HDV)) has been used in
neuroblastoma cells to reduce the expression of amyloid
precursor protein (APP) by 70% and the total secretion
of amyloid-beta peptides by 30%, thus raising the possi-
bility of ribozymes as therapeutics in AD [40].
DNAzymes
DNAzymes are synthetic single-stranded catalytic nucleic
acids that also have substrate binding arms to target
complementary mRNA and a cation-dependent catalytic
core. They have been shown to knock-down mutant HTT
mRNA constructs by 85% in a HEK293 cell model of HD
[41], but further research in this area is needed.
Genome editing for gene suppression
Gene suppression can also be achieved at the transcrip-
tional level, using effectors that bind to specific DNA
sequences. One such approach uses ZFPs which con-
tain a zinc finger domain that can be manipulated syn-
thetically to bind a DNA sequence of interest, fused to
a functional protein domain. Zinc finger nucleases
(ZFNs) cleave DNA at a particular target site, and zinc
finger transcriptional repressors (ZFTRs) are transcrip-
tion factor DNA-recognition motifs fused to a tran-
scriptional repressor domain. Delivery of such agents
would be through the use of viral vectors.
Potential advantages of this approach are the avoid-
ance of on-target and off-target toxicities of RNA
therapeutics and the elimination of all disease-causing
mRNA splice variants, not just those that possess the
target mRNA sequence [42]. The prospect of germ-
line treatment, which would benefit future genera-
tions, is also possible. In the case of HD, ZFPs
delivered intra-parenchymally using AAV vectors in a
transgenic mouse model of HD (R6/2) reduced mu-
tant HTT expression (without affecting wild-type
HTT expression) and led to improvements in neu-
ropathology and motor deficits [43]. The pharma-
ceutical company Sangamo, in conjunction with Shire
Pharmaceuticals, are planning to take this approach
forwards into clinical trials.
Other engineered nucleases include mega-nucleases,
transcription activator-like effector nucleases (TALENs)
and clustered regulatory interspaced short palindromic
repeat (CRISPR)/Cas9 systems [44]. CRISPR/Cas9 is an
endogenous mechanism within prokaryotic cells that recog-
nises and destroys foreign DNA. This system can be manip-
ulated to incorporate a synthetic guide RNA (gRNA) strand
that targets a particular DNA location for cutting, followed
by the insertion of DNA (e.g. stop codons) that essentially
inactivates the mutant allele [45]. The technique has been
demonstrated successfully in HD patient-derived fibro-
blasts, leading to the dramatic reduction of mutant HTT
RNA and mHTT protein [46].
In addition to repressing gene transcription, the ability
of these methods to target nuclease-induced scission
and repair offers the exciting possibility of actually cor-
recting genetic mutations (e.g. through the excision of
the expanded CAG repeat in HD)—leading to true gen-
ome editing. There is thus the exciting potential to treat
not just HD but any genetic cause of neurodegenerative
dementia using these techniques.
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Potential challenges in gene suppression
approaches
Drug delivery and administration
RNA interference
Because unmodified siRNAs do not readily cross the
blood–brain barrier (BBB), or the plasma membrane of
cells, researchers have used viral vectors to enable stable
expression of shRNAs and artificial miRNAs within de-
sirable brain regions. The most commonly used vectors
are recombinant adeno-associated virus (AAV) and
lentivirus (LV), both of which are non-pathogenic, trig-
ger minimal immune response and cannot replicate in
the host. AAVs remain as nuclear episomes and do not
integrate into the host genome, but result in stable gene
expression that is stronger than that of LVs. siRNA
sequences constitutively delivered through miRNA ex-
pression systems expressed from a viral vector should
minimise the requirement for repetitive administration.
There are multiple capsid serotypes of AAV, allowing for
specific cell-directed therapy [47, 48]. Unfortunately
many humans have pre-existing antibodies to certain
AAV serotypes that trigger a neutralising response
against the virus [49, 50]. It may be possible to screen
potential patients for this, and work is also being done
to engineer AAV capsids that evade these antibodies.
In the case of HD the primary site of pathology is the
striatum, thus RNAi treatments in animal models have
generally been delivered by bilateral direct injection or in-
fusion into the striatum, or the adjacent lateral ventricle
(resulting in widespread delivery throughout the brain)
[11]. However, HD also results in global brain pathology
and dysfunction as well as a peripheral metabolic pheno-
type. Recently, RNAi treatment targeted to the hypothal-
amus has been shown to reduce metabolic symptoms in
HD mouse models [51]. These administration techniques
would require stereotactic neurosurgery in patients, which
is extremely invasive and not without risk.
AAV serotype 9 (AAV9) crosses the BBB and trans-
duces neurons and glia in the brain, as well as a variety
of peripheral tissues, following a systemic, intravascular
injection [52]. A global targeting approach using jugular
vein injection of AAV9 expressing artificial miRNA into
transgenic HD mice showed reduced expression of
mHTT in the cortex, striatum, hypothalamus and hippo-
campus. This led to a reduction of cortical and striatal
atrophy, as well as reduced inclusion formation [53].
More recently, Deverman et al. described a capsid selec-
tion method, called Cre-recombination-based AAV tar-
geted evolution (CREATE), to generate AAV variants
with high CNS tropism. Following intravenous injection
in mice, the variant AAV-PHP.B transduced the majority
of neurons and astrocytes across multiple CNS regions,
with 40-fold greater efficacy than the current standard
(AAV9) [54]. These studies raise the possibility of future
peripheral administration of RNAi therapy in the treat-
ment of brain disorders.
Anti-sense oligonucleotides
ASOs also do not cross the BBB, but can be delivered
into the cerebrospinal fluid (CSF), either through intra-
thecal or intra-ventricular injection, as they are soluble
in artificial CSF. Once injected, ASOs are distributed to
the brain parenchyma and taken up into both neuronal
and glial cells. Unlike RNAi, ASOs are not regenerated
within the cell and have a half-life that varies depending
on the precise sequence and chemical structure. Repeated
dosing of the drugs is therefore required to sustain treat-
ment effect. ASOs display dose dependency and reversibil-
ity, and therefore the degree of protein lowering can be
controlled to achieve safe yet effective levels.
In the case of HD, ASOs delivered intra-ventricularly
to rodents led to > 75% reduction of target HTT mRNA
throughout the brain and spinal cord. In NHP brains,
ASOs delivered intrathecally were found in the spinal
cord, in the cortex and to a lesser extent in the deeper
brain structures [35]. Although ASOs achieve widespread
distribution throughout the brain after lumbar intrathecal
bolus delivery into the CSF [55], the highest tissue levels
are in areas adjacent to the CSF. This suggests that passive
diffusion may play an important role in drug distribution,
although the cardiac and respiration-associated oscillations
of CSF that propel the fluid along paravascular routes may
account for distribution to deeper structures. How-
ever, even in areas with low ASO levels, populations
of neuronal cell bodies containing higher levels of
ASO are found, suggesting that active transport
(anterograde or retrograde) also plays a part. Ultim-
ately, injection of ASOs into the CSF does lead to
drug distribution across wide areas of the CNS [11].
In the future, medical devices (e.g. implantable pumps)
may be able to replace the need for repeated lumbar
punctures to achieve regular intrathecal dosing of ASOs.
This would reduce the burden of administration for both
patients and medical professionals. Recently, the devel-
opment of peptide-conjugated ASOs delivered through
intravenous injection (IVI) has been shown to have
broad peripheral and CNS distribution in a mouse
model of severe SMA. A profound improvement in
mean survival from 12 to 456 days was also seen [56].
IVI is a far less invasive method of drug administration
than intrathecal injection, and there is hope that this
could one day prove to be an effective method of drug
delivery in patients.
Off-target effects
Off-target effects are unintended consequences following
the administration of gene suppression therapies. They
include interference with non-target mRNA transcripts
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and activation of the immune system in response to
drug delivery. In the case of siRNAs and ASOs, there is
potential to bind mRNA sequences that share sequence
homology to the desired target, thus causing down-
regulation of unrelated proteins [57]. Because struc-
turally related microRNAs modulate gene expression
largely via incomplete complementarity base pair inter-
actions with a target mRNA, the introduction of an
siRNA may cause unintended off-targeting. For ASOs,
selecting unique target sequences that do not appear
anywhere else in the genome can overcome this risk. In
the treatment of HD, both ASOs and RNAi targeting the
mRNA CAG expansion carry the possibility of affecting
other PolyQ containing proteins.
When a mammalian cell encounters a double-stranded
RNA such as an siRNA, the cell may mistake it as a viral
by-product and mount an immune response. siRNAs
have been shown to up-regulate the expression of
interferon (IFN)-stimulated genes through the activa-
tion of protein kinase R (PKR) [58]. siRNAs have also
been shown to activate certain toll-like receptors
(TLRs), leading to the expression of pro-inflammatory
cytokines [59–61]. Careful design of gene suppression
effectors to generate high complementarity, and
chemical modifications that enhance their stability
and reduce immunogenicity, can mitigate some of
these effects [9].
Saturation of the RNAi pathway
Delivery of shRNA effectors has been shown to overload
exportin-5, thus preventing the maturation of endogen-
ous miRNA and effectively shutting down the cellular
miRNA pathway [62, 63]. Saturation of the endogenous
RNAi pathway can in turn lead to detrimental effects
such as liver toxicity [64, 65]. This effect can be miti-
gated by selecting promoters for only modest expression
of shRNAs, or by the co-expression of recombinant
exportin-5 [64, 66]. Artificial miRNAs are better toler-
ated and synthetic siRNAs are able to bypass the nuclear
processing step altogether [17, 67]. This particular issue
does not arise when using ASOs, as the RNAi pathway
is not co-opted, and ASOs have clear dose-dependent
and reversible effects.
Alternative pathways to neurotoxicity
In theory, certain gene suppression strategies may not be
as effective in cases where there is evidence of abnormal
RNA processing or toxicity of the RNA itself. In the case
of HD, aberrant mRNA splicing has been shown to gener-
ate the production of a pathogenic HTT exon 1 fragment
from the CAG-expanded HTT gene [68], which may evade
RNAi effectors that act on mature mRNA transcripts. De-
pending on the timing of formation of this alternatively
spliced mRNA variant, it may also avoid potential ASO
binding. The CAG-expanded mRNA has itself been pro-
posed as a source of toxicity in HD [69]; prevention of its
formation would not be achieved by RNAi, although
ASOs acting at the pre-mRNA level may be effective at re-
ducing RNA-mediated toxicity. Both aberrant splicing and
RNA toxicity could be eliminated, however, using genome
editing approaches.
The extent to which these alternative pathways of
toxicity exist and contribute to the disease phenotype in
other forms of dementia could impact on the success of
various gene suppression approaches for treatment.
Assessment of target engagement
Interpretation of drug effect in early-stage, proof-of-
concept clinical trials can be facilitated by measuring of
the ability of the therapy to engage with its target.
Methods for assessing target engagement include im-
aging modalities and measurement of target RNA or
protein in an easily accessible biofluid or tissue sample.
To assess target engagement directly, brain-imaging
techniques that allow for quantitation of target protein
in vivo are usually required. Recently, novel radiotracers
for PET imaging have been developed to detect brain tau
deposition [70], which may offer a direct assessment of
target engagement by tau-lowering therapies. These tech-
niques are relatively new, and identification of tracers with
sufficient specificity to quantitate the protein of interest
has proven challenging. As the field advances, PET im-
aging will probably become a very valuable tool for evalu-
ation of target engagement of gene suppression therapies.
Quantification of target RNA or protein in a biofluid
or tissue sample is another useful method for evaluating
target engagement. For neurodegenerative conditions,
where the target tissue is in the brain, collection of tar-
get tissue samples is impractical; however, collection of
CSF samples is straightforward, and changes in neuronal
proteins measured in CSF can be expected to reflect
changes in brain tissue. Assays to detect CSF β-amyloid
and tau protein are already used in the clinical evalu-
ation of AD, and are incorporated into most clinical tri-
als of AD. Likewise, assays to detect alpha-synuclein are
sometimes used to assess target engagement in PD trials
[71]. In the case of HD, an ultrasensitive single-molecule
counting mHTT immunoassay has been developed that
can accurately detect very low amounts of mHTT in
the CSF. The level of mHTT in the CSF has been
shown to correlate with disease stage and is also raised
in pre-manifest HD [72].
It is worth noting that levels of target proteins in the
CSF are an indirect reflection of absolute protein levels at
actual sites of pathology in the brain parenchyma. How-
ever, using research in animals, it is possible to develop
models of the relationship between drug pharmacokinetics
(PK) and pharmacodynamics (PD) that predict target
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engagement in the brain regions of interest. Such models
relate the reduction of expression of a gene in target tissue
with parameters that can be measured in humans, such as
the protein product of that gene’s expression in CSF.
Studies in non-human primates, where brain anatomy is
similar to humans, can provide a guide for interpretation
of target engagement markers in biofluids. In fact, animal
data were shown to translate well to humans during clin-
ical development of nusinersen, an ASO for the treatment
of patients with spinal muscular atrophy (SMA). In
this programme, autopsy material was available from
a few patients who received nusinersen during clinical
development, and levels of ASO and target engage-
ment markers in tissue were found to be well aligned
with predictions from the pre-clinical PK–PD models,
supporting the premise that thorough characterisation
of drug pharmacology in relevant animal species is
important for planning and interpretation of data in
humans [73].
Initiation of gene suppression therapies
As with any disease-modifying treatment for neurode-
generative disease, timing of intervention is crucial. In
the case of HD, predictive genetic testing is available
to those whose family history puts them at risk, and
mutation carriers could potentially start gene suppres-
sion treatment before any clinical symptoms appeared.
The goal would then be to initiate treatment just be-
fore the onset of pathology and prevent the disease
from ever being manifest. Objective biomarkers are re-
quired to pinpoint pathology onset and when to start
treatment. Large, prospective, longitudinal natural his-
tory and deep phenotyping studies have been under-
taken in HD [74] and suggest that pathology may be
detectable on volumetric neuroimaging 10.8 years
prior to symptom onset [75–78]. Such observational
studies are critical in other diseases to guide the tim-
ing of intervention with disease-modifying therapeu-
tics to intercept early pathology.
Allele specificity
ASOs can be developed to target mRNA from both the
mutant allele and the wild-type allele equally or to
favour the mutant allele over the wild-type allele. The
former, non-allele-specific, approach has the advantages
of addressing the entire HD population and maintaining
flexibility for ASO design across the entire gene, increas-
ing the likelihood of identifying a specific, potent and
well-tolerated ASO. The potential disadvantage for non-
allele-specific ASOs lies in reduction of the wild-type al-
lele. An allele-specific approach can be achieved by tar-
geting either the CAG expansion or a sequence
containing a specific single nucleotide polymorphism
(SNP) found only on the mutant allele. Allele-specific
approaches have the advantage of preferential reduction
of the mutant protein. Potential disadvantages include
blunted potency and tolerability due to severe limitations
on sequence space, undesirable reduction of other pro-
teins containing CAG repeats not linked to disease (with
CAG-targeting ASOs) and addressing only a subset of
the disease population (with SNP-targeting ASOs).
In the case of HD, embryonic knockout of Htt is lethal
[79] and its complete inactivation in the rodent brain
causes a progressive neurological phenotype [80]. How-
ever, as mentioned previously, partial HTT lowering has
been shown to be well tolerated in NHPs [30, 35] and
complete inactivation of HTT in adulthood has been
shown to be well tolerated in mice carrying the human
HTT transgene [81]. Intuitively, strategies to silence the
mutant allele whilst leaving the normal allele unaffected
may be desirable to prevent any potential longer-term
detrimental effects from loss of wild-type protein func-
tion. It is noteworthy, however, that ASOs do not ever
achieve complete gene suppression. Even at high doses
of ASO, residual HTT will be produced, mitigating risk
of non-allele-specific approaches.
ASOs complementary to the expanded CAG have
been produced which have up to 6-fold selectivity for
mHTT over HTT [82–84]; selectivity is thought to arise
as longer CAG transcripts provide binding sites for
multiple ASOs. One potential drawback of this strategy
is that other polyQ-containing proteins may be affected,
and the potency of CAG targeting therapies is not as
great as for other approaches. BioMarin Pharmaceuticals
have, however, very recently carried out a study showing
that an ASO with sequence (CUG)7 successfully tar-
geted the expanded CAG repeat in mutant Htt mRNA
in two different mouse models of HD and that this led
to phenotypic improvement [85].
SNPs have been identified that reside only on the mu-
tant HTT allele [86, 87], with siRNAs designed to target
these specific SNPs. Three such SNPs have been identi-
fied that could be used to treat a majority of patients in
Europe and the USA [88]. A recent study has shown the
feasibility of allele selective suppression in HD patient
primary ex-vivo myeloid cells when using siRNA to tar-
get one of these potential SNPs, although the other
SNPs tested did not achieve any allele selectivity [89].
This was thought to be due to the nucleotide sequence
and tertiary structure of the transcript surrounding the
base mismatch, and therefore a lower proportion of HD
patients have targetable SNPs using this siRNA approach
than originally thought.
As mentioned previously, ASOs could also be used in
a SNP-targeting approach. An advantage of ASOs over
siRNAs is that they can target SNPs present in intronic
sequences, due to their capacity to bind pre-mRNA in
the nucleus rather than only mature mRNA transcripts
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in the cytoplasm. ASOs targeting mutant-allele linked
SNPs have been designed that lead to 50-fold selectivity
of the mHTT allele over the normal allele [90–92].
Three to five ASOs targeting different SNP sites would
be needed to treat 80% of HD patients [93]. Wave Life
Sciences are initiating clinical trials of two ASOs target-
ing SNP-containing regions of HTT mRNA; this involves
screening potential trial subjects for the presence of
these SNPs before allocation to one or other of the com-
pounds [94].
Recent and ongoing clinical trials of gene
suppression
The first human clinical trial of intrathecal delivery of
ASOs for the treatment of a neurodegenerative condi-
tion was carried out in patients with amyotrophic lateral
sclerosis (ALS) [3]. Inherited mutations in SOD1 ac-
count for 13% of familial ALS and 2% of all ALS, and
cause disease through a toxic gain-of-function of SOD1
protein. An ASO targeting SOD1 mRNA was shown to
reduce both wild-type and mutant SOD1 (i.e. non-allele
selective) in transgenic mice and in human cell models
of ALS [95, 96]. A phase 1 trial carried out by Ionis
Pharmaceuticals has since demonstrated the safety and
tolerability of intrathecal infusion of this drug in ALS
patients and has proven that the drug is distributed to
spinal cord tissues following injection and is detectable
in the CNS 3 months following injection [3]. Having
demonstrated the feasibility of this approach, Ionis
Pharmaceuticals, in conjunction with Biogen, is cur-
rently undertaking a phase 1/2a clinical study of a more
potent ASO (ISIS-SOD1Rx) in ALS associated with a
SOD1 mutation [97].
As mentioned previously, another phase 1/2a clinical
trial is also currently being undertaken by Ionis to test
the safety and tolerability of a MOE-modified ASO tar-
geting human HTT delivered by lumbar intrathecal
bolus administration to early-stage HD patients. The
trial includes neuroimaging assessments and exploratory
endpoints to assess the effect on cognitive, motor and
neuropsychiatric symptoms [1]. A clinical trial of AAV2-
delivered anti-HTT miRNA, which has shown promise
in NHPs [29], is also being planned to initiate in the
next few years [98].
Patients with SMA type 1 (infantile onset) have been
treated with lumbar intrathecal bolus injections of an
MOE-modified ASO (Nusinersen), and have shown dra-
matic improvement [34]. This is an important result for
the field, but it is worth noting that Nusinersen differs
mechanistically from other ASOs because it does not
trigger RNAse H1-induced cleavage of the target mRNA,
and therefore does not lead to “gene suppression”.
Infants with SMA type 1 have homozygous gene muta-
tions or deletion of SMN1, leading to a lack of survival
motor neuron (SMN) protein and the death of motor
neurons, which are particularly reliant on it. Nusinersen
in fact alters the splicing of the mRNA of another gene,
SMN2, that usually encodes a non-functional SMN pro-
tein, and in doing so increases the amount of functional
SMN available in the cell. The phase 3 ENDEAR trial of
this drug showed such promising efficacy in interim ana-
lysis that urgent work has already begun on an extended
access programme to widen the availability of the drug
to those not in a clinical trial [99]. The drug (marketed
as Spinraza™) received expedited approval by the FDA
[100] for all forms of SMA in paediatric and adult pa-
tients, and is administered by lumbar intrathecal bolus
injection at 4-month intervals. The success of Nusinersen
is encouraging; however, infantile SMA is an aggressive
and rapidly progressive disease which manifests in the first
few weeks or months of life, and is generally fatal over
1–2 years. Therefore positive treatment effects could be
easily and rapidly discerned in the clinical trial setting.
The outcome of gene suppression therapies for most
other neurodegenerative diseases will most probably
take longer to elucidate, as positive effects may not be
so striking.
Future gene suppression targets in
neurodegeneration
Recently DeVos et al. [4] have shown that treatment with
tau-reducing ASOs prevents neuronal loss in a mouse
model of tauopathy. Tau is a microtubule-associated pro-
tein in neurons, which becomes hyper-phosphorylated,
misfolds and forms insoluble neurofibrillary tangles
(NFTs) in AD. The close temporal and spatial relationship
between tau pathology and neurodegeneration is thought
to underlie the widespread neuronal loss and progressive
dementia seen in this condition. Indeed mutations in the
MAPT gene, which encodes tau protein, are causative for
another neurodegenerative disease—frontotemporal lobar
degeneration (FTLD). This study demonstrated improved
survival and histopathology in a mouse model of tauopa-
thy, and also showed tau protein reduction in CNS tissues
and CSF in non-human primates following intrathecal
bolus administration of ASOs targeting MAPT mRNA.
This opens up the exciting potential for gene suppression
treatments of tau as a therapeutic avenue for AD and other
tauopathies such as progressive supranuclear palsy (PSP),
and clinical trials of tau-lowering therapies are imminent.
The possibility of treatment with ASOs that reduce
pathogenic splice variants of C9orf72 is also under investi-
gation for the treatment of amyotrophic lateral sclerosis
(ALS) and frontotemporal dementia (FTD). In the future,
an ASO that suppresses alpha-synuclein gene (SNCA)
expression to reduce alpha-synuclein protein might have
utility in limiting the progression of PD [5]. In addition,
an ASO targeting leucine-rich-repeat kinase 2 (LRRK2)
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(mutations of which are the major cause of familial late-
onset PD) has been shown to reduce the spread of alpha-
synuclein pathology in the mouse brain [6]. There may be
great benefit in preventing the cortical dissemination of
alpha-synuclein pathology, to target the cognitive decline
and dementia that will eventually afflict more than 80% of
PD patients and is one of the most feared consequences
for those developing PD.
Spinocerebellar ataxia type 2 (SCA2) is an autosomal-
dominant, adult-onset neurodegenerative disease caused
by a polyglutamine expansion in the ataxin-2 gene
(ATXN2). Scoles et al. [7] recently carried out a screen
of multiple ASOs directed against ATXN2 mRNA (non-
allele specific) and tested their most promising candidate
in two mouse models. Following intracerebroventricular
injection, this ASO localised to Purkinje cells and re-
duced cerebellar ATXN2 expression and levels of cere-
bellar ATXN2. This was also associated with significantly
improved motor function [7].
An ASO lowering ATXN2 has also been shown to in-
crease the lifespan and improve motor symptoms in a
mouse model of TDP-43 proteinopathy [8]. Nearly all
patients with ALS have aggregates of TDP-43 (an RNA-
binding protein) in their brain and spinal cord, and TDP-
43 pathology is also found in 50% of cases of FTD. Genetic
lowering of ataxin-2 (using ataxin-2 knockout mice
crossed with TDP-43 transgenic mice) leads to a reduction
in TDP-43 aggregation. However, therapies that suppress
TDP-43 are not viable due to the protein’s vital cellular
functions. The finding that ATXN2 lowering markedly ex-
tends survival in these mice lends promise to this ap-
proach for the treatment of sporadic ALS and FTD, and is
the first example of an ASO therapy targeting a modifier
gene that is not directly causative of the disease [8].
Conclusions
Gene suppression technologies have made enormous
progress in the last 20 years. Clinical trials of ASOs are
already underway and trials of RNAi and genome editing
using ZFNs are not far behind. The relative advantages
of ASOs and RNAi are summarised in Table 1. Lessons
learnt from work carried out in the field of HD, as well
as ALS and SMA, can be applied to other neurodegener-
ative diseases in which the causative gene mutation or
disease protein is known.
Challenges with drug delivery of gene suppression
agents have been researched extensively and largely
overcome. In the case of ASOs, lumbar intrathecal bolus
delivery is proving to be a viable option, and in the case
of RNAi, modification of viral vectors has allowed for
tolerability and efficacy. Administration of viral vectors
either through directed brain injection/infusion to target
specific sites, or through peripheral vascular injection
leading to global CNS effects, has been tolerated in ani-
mal models.
The next few years will see further expansion in the
clinical evaluation of gene suppression therapies for the
treatment of dementia, both in terms of the number of
neurodegenerative diseases targeted and the number of
patients treated. Thus there is real hope that, in the face
of aging populations and the ever-increasing incidence
of dementia, we will in the near future be able to
offer effective treatments to sufferers. Moreover, with
advances in biomarker technology that can detect the
increasingly understood evolution of pathology in
asymptomatic individuals, the prospect of early
disease interception to prevent the symptomatic
expression of these neurodegenerative disorders is a
tantalising possibility.
Table 1 Relative advantages of RNAi and ASOs as a strategy to achieve gene suppression
Advantages of different approaches to post-transcriptional gene suppression
RNA interference Anti-sense oligonucleotides
• siRNAs do not cross the BBB and if introduced into CSF cannot achieve
widespread distribution in the CNS parenchyma. However, siRNA
effector sequences can be constitutively delivered through miRNA
expression systems expressed from a viral vector.
• siRNAs can lead to very high levels of translational suppression and
lowering of target protein, if this is desired.
• siRNAs have prolonged effects in terms of gene suppression and so
there is potentially minimal or no need for repetitive administration.
However, this is a type of gene therapy, which is irreversible, and there
are no antidotes.
• Through peripheral administration in neonates or very early infancy,
global or larger CNS areas can be targeted.
• ASOs do not cross an intact BBB. However, ASOs are soluble in artificial
CSF and can be delivered directly into the CSF space. Once introduced
into the CSF, modified ASOs achieve widespread distribution in the CNS
parenchyma and enter neuronal and glial cells.
• ASOs have predictable, dose-dependent pharmacokinetics, enabling
modulation of dose to achieve the desired level of pharmacological
activity; with intrathecal bolus dosing every few months in
symptomatic patients and potentially less frequently in pre-
symptomatic patients.
• ASO pharmacological effects are reversible and gene suppression
reverses when treatment is stopped.
• In addition to exonic regions, ASOs are able to target intronic regions
as they bind to pre-mRNA rather than only mature transcripts. Thus they
have more mRNA “real estate” from which to find the ideal ASO drug
candidate, and can be used to treat a wider range of diseases.
• Avoids saturation of RNAi pathways which can lead to liver toxicity.
• No need for viral vector delivery, and therefore avoids the generation
of an immune response.
ASO anti-sense oligonucleotide, BBB blood–brain barrier, CSF cerebrospinal fluid, CNS central nervous system, miRNA micro-RNA, RNAi RNA interference, siRNA small
interfering RNA
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